Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF) - Contacts and Locations

Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF) (PreCONDITION)

This study is currently recruiting participants.

Study NCT00699712. Last updated on October 19, 2008. Information provided by Nile Therapeutics

Please refer to this study by its ClinicalTrials.gov identifier: NCT00699712

Contacts


Contact: Nancy Vinh	415-875-7885	nvinh@nilethera.com

Contact: Jennifer Hodge	415-875-7884	jhodge@nilethera.com

Locations


Russian Federation, Russia
	Russian Academy of Medical Sciences	Recruiting
	Moscow, Russia, Russian Federation, 121552

Sponsors and Collaborators

Nile Therapeutics

Momentum Research Inc.

Investigators


Study Director:	Hsiao Lieu, MD	Nile Therapeutics Inc.

Study Director:	Gad Cotter, MD	Momentum Research Inc.